Biological
VE303
VE303 is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
completed375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452
completedphase_2
VE303 for Treatment of Hepatic Encephalopathy (HE)
NCT04899115
completedphase_2
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT03788434
completedphase_1
First-in-human Study of VE303 in Healthy Adult Volunteers
NCT04236778
Clinical Trials (4)
Showing 4 of 4 trials
NCT06237452Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT04899115Phase 2
VE303 for Treatment of Hepatic Encephalopathy (HE)
NCT03788434Phase 2
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT04236778Phase 1
First-in-human Study of VE303 in Healthy Adult Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4